Weiguo Dai

Johnson & Johnson, USA

Dr. Weiguo Dai is currently a Scientific Director in Drug Product Development in Johnson and Johnson. He is also one of 62 individuals elected Inaugural JANSSEN FELLOWs, the highly prestigious scientific honor awarded to internationally recognized top scientists within Johnson and Johnson Pharmaceutical R&D. Dr. Dai’s research and innovation have focused on improving both biological and small molecule drug products through design and development of novel formulations, proprietary delivery technologies/devices and processes. His technology innovations have directly led to the launch of commercial products, and established development projects for clinical trials. Dr. Dai is the recipient of several prestigious awards including Johnson and Johnson Corporate 2011 Philip B. Hofmann Research Scientist Award in recognition of his “Outstanding Achievement in the Field of Research and Development”. Also Dr. Dai serves as 2012-2013 Vice Chair of Physical Pharmacy and Biopharmaceutics (PPB) section in American Association of Pharmaceutical Scientists (AAPS). Additionally, he is currently President-Elect of Sino-American Pharmaceutical Professionals Association (SAPA)-Greater Philadelphia. Dr. Dai has authored/co-authored over 40 peer-reviewed journal articles, and currently serves on the Editorial Advisory Board for several peer-reviewed pharmaceutical journals. He also serves as an Adjunct Professor for Thomas J. Long School of Pharmacy and Health Sciences at University of the Pacific in California, USA, and has been a frequently invited speaker for numerous international conferences and workshops. Dr. Dai earned his PhD degree from The Johns Hopkins University in 1996, and has over 17 years of technology and drug product development experience in biotech/pharmaceutical companies, including Guilford Pharmaceuticals (now Eisai), Amgen, ALZA, Centocor, and Johnson and Johnson.

Biography Updated on 11 December 2013

Scholarly Contributions [Data Provided by scopus]